RxDoctor Payments Data

Ayodele Atolagbe, MD

Surgery · Jamaica, NYNPI 1255686085

Payments from drug & device makers

$701in general payments, 2019–2025

Across 35 payments — averaging $20.04 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Johnson & Johnson$288
  • Otsuka America Pharmaceutical, Inc.$229
  • Alkermes, Inc.$84
  • Neurocrine Biosciences, Inc.$47
  • Teva Pharmaceuticals USA, Inc.$37
  • Axsome Therapeutics, Inc.$18

What the payments were for

  • Food & beverage$701100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

20
21
22
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

$701 in reported general payments places this provider in the 40th percentile of 1,596 surgery providers in New York.

See all surgery providers in New York

Medicare billing

Part B allowed, 2024
$281,721
Medicare patients
109
Services billed
2,733

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
IngrezzaValbenazine Tosylate21$163,181
EliquisApixaban121$76,355
TrulicityDulaglutide63$63,900
JanuviaSitagliptin Phosphate100$62,625
LinzessLinaclotide95$54,731
JardianceEmpagliflozin86$53,942
OzempicSemaglutide42$45,353
Invega SustennaPaliperidone Palmitate17$40,972
Diclofenac Epolamine70$40,621
MyrbetriqMirabegron79$37,499
XareltoRivaroxaban61$36,204
EntrestoSacubitril/Valsartan51$35,779
Trelegy ElliptaFluticasone/Umeclidin/Vilanter38$28,790
FarxigaDapagliflozin Propanediol37$26,575
TradjentaLinagliptin41$23,984

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Neurocrine Biosciences, Inc.Ingrezza$47$163,18121 claims
Johnson & JohnsonInvega Sustenna, Xarelto$288$77,17678 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 40th percentile of 1,596 surgery providers in New York.

Other surgery in Jamaica

See the full list for New York

Where these figures come from

Is this you, or does something look wrong? →